garetosmab

Phase 3Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Fibrodyplasia Ossificans Progressiva (FOP)

Conditions

Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO)

Trial Timeline

Oct 13, 2021 → Oct 8, 2022

NCT ID

NCT04577820

About garetosmab

garetosmab is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Fibrodyplasia Ossificans Progressiva (FOP). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04577820. Target conditions include Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07301450	Pre-clinical	Active	—	—	Fibrodysplasia Ossificans Progressiva (FOP)
NCT04577820	Phase 3	Withdrawn	Oct 13, 2021	Oct 8, 2022	Fibrodyplasia Ossificans Progressiva (FOP)